X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Eyenovia re-acquired the rights to MicroPine in the U.S. and Canada, expanding its phase III pipeline. MicroPine, an investigational ophthalmic spray of atropine delivered by Optejet device, is being evaluated as a potential treatment for pediatric progressive myopia.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: MicroPine
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eyenovia
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Acquisition January 16, 2024
Details:
Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ocular surface pain.
Lead Product(s): Lifitegrast
Therapeutic Area: Ophthalmology Product Name: Xiidra
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: $2,500.0 million Upfront Cash: $1,750.0 million
Deal Type: Divestment September 29, 2023
Details:
MIEBO (perfluorohexyloctane ophthalmic solution) is used for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only prescription eye drop approved for DED that directly targets tear evaporation.
Lead Product(s): Perfluorohexyloctane
Therapeutic Area: Ophthalmology Product Name: Miebo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
The financing will fund the acquisition Xiidra (lifitegrast ophthalmic solution), a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.
Lead Product(s): Lifitegrast
Therapeutic Area: Ophthalmology Product Name: Xiidra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 11, 2023
Details:
Through the acquisition, Bausch & Lomb expands its OTC product line by obtaining Blink portfolio of eye drops including, Blink® Tears (polyethylene glycol).
Lead Product(s): Macrogol
Therapeutic Area: Ophthalmology Product Name: Blink® Tears
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Johnson & Johnson
Deal Size: $106.5 million Upfront Cash: $106.5 million
Deal Type: Acquisition July 06, 2023
Details:
Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ocular surface pain.
Lead Product(s): Lifitegrast
Therapeutic Area: Ophthalmology Product Name: Xiidra
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: $2,500.0 million Upfront Cash: $1,750.0 million
Deal Type: Divestment June 30, 2023
Details:
Miebo (perfluorohexyloctane) is the first drug approved by USFDA to treat dry eye disease associated with Meibomian gland dysfunction. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.
Lead Product(s): Perfluorohexyloctane
Therapeutic Area: Ophthalmology Product Name: Miebo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novaliq
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
NOV03 (Perfluorohexyloctane) is the first drug developed to treat dry eye disease associated with Meibomian gland dysfunction in a highly effective way. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.
Lead Product(s): Perfluorohexyloctane
Therapeutic Area: Ophthalmology Product Name: 37926
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novaliq
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
Results with Xipere (triamcinolone acetonide) showed statistically significant reduction in tumor growth rate compared to each patient’s documented growth rate at study entry, and an 88.9% tumor control rate.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Clearside Biomedical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
NOV03 (perfluorohexyloctane) A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).
Lead Product(s): Perfluorohexyloctane
Therapeutic Area: Ophthalmology Product Name: 37926
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novaliq
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
